---
document_datetime: 2025-12-02 04:51:44
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/orphacol.html
document_name: orphacol.html
version: success
processing_time: 0.1334267
conversion_datetime: 2025-12-29 19:56:19.962035
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Orphacol

[RSS](/en/individual-human-medicine.xml/65542)

##### Authorised

This medicine is authorised for use in the European Union

cholic acid Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Orphacol](#more-information-on-orphacol-32620)
- [More information on Orphacol](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Orphacol. It explains how the European Medicines Agency assessed the medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Orphacol.

For practical information about using Orphacol, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Orphacol and what is it used for?

Orphacol is a medicine containing cholic acid, a substance found in the bile, which is used to digest fats.

It is used to treat adults and children from one month of age who have a genetic abnormality that makes them unable to produce bile. Orphacol is used in patients who do not have enough of two specific liver enzymes (3?-hydroxy-?5-C27-steroid oxidoreductase or ?4-3-oxosteroid-5?-reductase). This makes their liver unable to produce enough of the main components of bile, called primary bile acids, such as cholic acid. When these primary bile acids are lacking, the body produces abnormal bile acids instead which can damage the liver, potentially leading to life-threatening liver failure.

Because the number of patients with inborn errors in primary bile acid synthesis is low, the condition is considered 'rare', and Orphacol was designated an 'orphan medicine' (a medicine used in rare diseases) on 18 December 2002.

## How is Orphacol used?

The medicine can only be obtained with a prescription and treatment with Orphacol should be started and supervised by a doctor specialised in liver disease.

Orphacol is available as capsules and should be taken every day at approximately the same time, with a meal. The daily dose is between 5 and 15 mg per kilogram body weight, adjusted for each patient according to the state of their bile acid, with a minimum daily dose of 50 mg and a maximum of 500 mg. For small children who cannot swallow capsules, the contents can be mixed in with infant formula or juice. Treatment should be stopped if liver function does not improve within three months.

## How does Orphacol work?

Cholic acid is the main primary bile acid produced by the liver. The cholic acid contained in Orphacol replaces the patient's missing cholic acid. This helps to decrease the production of abnormal bile acids and contributes to the normal activity of bile in the digestive system, thereby relieving the symptoms of the condition.

## What benefits of Orphacol have been shown in studies?

Because cholic acid is a well known substance, and its use in these enzyme deficiencies is well established, the applicant presented data from the scientific literature. The applicant presented data on 49 patients with inborn errors in primary bile acid synthesis, taken from the scientific literature (38 patients with 3?-hydroxy-?5-C27-steroid oxidoreductase deficiency and 11 patients with ?4-3-oxosteroid-5?-reductase deficiency). It compared the outcomes of 28 patients who received cholic acid with others who were given different bile acids or did not receive bile-acid treatment.

In the scientific literature, cholic acid treatment was shown to reduce the amount of abnormal bile acids in patients, to restore the normal functions of the liver and to help delay or prevent the need for a liver transplant.

## What are the risks associated with Orphacol?

The side effects seen with Orphacol were diarrhoea, pruritus (itching), increases in transaminases (liver enzymes) and possibly gallstones, although their frequency could not be reliably estimated from the available limited data.

Orphacol should not be used in people who may be hypersensitive (allergic) to cholic acid or any of the other ingredients. It must not be taken by patients already taking phenobarbital, a medicine used to treat epilepsy.

## Why is Orphacol approved?

The Committee for Medicinal Products for Human Use (CHMP) noted that the use of cholic acid to treat inborn errors in primary bile-acid synthesis was well established in medical practice and documented in the scientific literature, although the number of documented cases was low due to the rarity of the condition. It decided that based on the evidence from the scientific literature, Orphacol's benefits are greater than its risks and recommended that it be given marketing authorisation.

Orphacol has been authorised under 'exceptional circumstances'. This means that because the disease is rare, it has not been possible to obtain complete information about Orphacol. Every year, the European Medicines Agency will review any new information that may become available and this summary will be updated as necessary.

## What information is still awaited for Orphacol?

Since Orphacol has been approved under exceptional circumstances, the company that markets Orphacol will establish a database of patients treated with Orphacol to monitor the safety and effectiveness of the treatment, and will submit the results to the CHMP at regular, specified intervals.

## What measures are being taken to ensure the safe and effective use of Orphacol?

A risk-management plan has been developed to ensure that Orphacol is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Orphacol, including the appropriate precautions to be followed by healthcare professionals and patients.

The company that makes Orphacol will also provide doctors in all Member States who will use Orphacol with a pack containing product literature and information regarding the correct diagnosis of these disease conditions, the risks of side effects and how to use the medicine properly.

## Other information about Orphacol

The European Commission granted a marketing authorisation valid throughout the European Union for Orphacol on 12 September 2013.

For more information about treatment with Orphacol, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Orphacol : EPAR - Summary for the public

English (EN) (85.95 KB - PDF)

**First published:** 02/10/2013

**Last updated:** 02/10/2013

[View](/en/documents/overview/orphacol-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-526)

български (BG) (106.45 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/bg/documents/overview/orphacol-epar-summary-public_bg.pdf)

español (ES) (84.98 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/es/documents/overview/orphacol-epar-summary-public_es.pdf)

čeština (CS) (104.07 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/cs/documents/overview/orphacol-epar-summary-public_cs.pdf)

dansk (DA) (87.31 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/da/documents/overview/orphacol-epar-summary-public_da.pdf)

Deutsch (DE) (87.58 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/de/documents/overview/orphacol-epar-summary-public_de.pdf)

eesti keel (ET) (82.51 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/et/documents/overview/orphacol-epar-summary-public_et.pdf)

ελληνικά (EL) (128.23 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/el/documents/overview/orphacol-epar-summary-public_el.pdf)

français (FR) (86.82 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/fr/documents/overview/orphacol-epar-summary-public_fr.pdf)

hrvatski (HR) (98.71 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/hr/documents/overview/orphacol-epar-summary-public_hr.pdf)

italiano (IT) (87.57 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/it/documents/overview/orphacol-epar-summary-public_it.pdf)

latviešu valoda (LV) (118.5 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/lv/documents/overview/orphacol-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (103.09 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/lt/documents/overview/orphacol-epar-summary-public_lt.pdf)

magyar (HU) (100.86 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/hu/documents/overview/orphacol-epar-summary-public_hu.pdf)

Malti (MT) (105.3 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/mt/documents/overview/orphacol-epar-summary-public_mt.pdf)

Nederlands (NL) (87.92 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/nl/documents/overview/orphacol-epar-summary-public_nl.pdf)

polski (PL) (104.63 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/pl/documents/overview/orphacol-epar-summary-public_pl.pdf)

português (PT) (87.14 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/pt/documents/overview/orphacol-epar-summary-public_pt.pdf)

română (RO) (101.86 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/ro/documents/overview/orphacol-epar-summary-public_ro.pdf)

slovenčina (SK) (103.6 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/sk/documents/overview/orphacol-epar-summary-public_sk.pdf)

slovenščina (SL) (98.48 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/sl/documents/overview/orphacol-epar-summary-public_sl.pdf)

Suomi (FI) (87.07 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/fi/documents/overview/orphacol-epar-summary-public_fi.pdf)

svenska (SV) (87.77 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/sv/documents/overview/orphacol-epar-summary-public_sv.pdf)

Orphacol : EPAR - Risk-management-plan summary

English (EN) (105.97 KB - PDF)

**First published:** 28/07/2021

[View](/en/documents/rmp-summary/orphacol-epar-risk-management-plan-summary_en.pdf)

## Product information

Orphacol : EPAR - Product Information

English (EN) (344.79 KB - PDF)

**First published:** 02/10/2013

**Last updated:** 08/10/2024

[View](/en/documents/product-information/orphacol-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-378)

български (BG) (430.53 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

08/10/2024

[View](/bg/documents/product-information/orphacol-epar-product-information_bg.pdf)

español (ES) (349.43 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

08/10/2024

[View](/es/documents/product-information/orphacol-epar-product-information_es.pdf)

čeština (CS) (378.77 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

08/10/2024

[View](/cs/documents/product-information/orphacol-epar-product-information_cs.pdf)

dansk (DA) (368.54 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

08/10/2024

[View](/da/documents/product-information/orphacol-epar-product-information_da.pdf)

Deutsch (DE) (368.79 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

08/10/2024

[View](/de/documents/product-information/orphacol-epar-product-information_de.pdf)

eesti keel (ET) (344.67 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

08/10/2024

[View](/et/documents/product-information/orphacol-epar-product-information_et.pdf)

ελληνικά (EL) (432.04 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

08/10/2024

[View](/el/documents/product-information/orphacol-epar-product-information_el.pdf)

français (FR) (334.54 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

08/10/2024

[View](/fr/documents/product-information/orphacol-epar-product-information_fr.pdf)

hrvatski (HR) (402.94 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

08/10/2024

[View](/hr/documents/product-information/orphacol-epar-product-information_hr.pdf)

íslenska (IS) (384.78 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

08/10/2024

[View](/is/documents/product-information/orphacol-epar-product-information_is.pdf)

italiano (IT) (376.57 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

08/10/2024

[View](/it/documents/product-information/orphacol-epar-product-information_it.pdf)

latviešu valoda (LV) (360.66 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

08/10/2024

[View](/lv/documents/product-information/orphacol-epar-product-information_lv.pdf)

lietuvių kalba (LT) (347.67 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

08/10/2024

[View](/lt/documents/product-information/orphacol-epar-product-information_lt.pdf)

magyar (HU) (414.13 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

08/10/2024

[View](/hu/documents/product-information/orphacol-epar-product-information_hu.pdf)

Malti (MT) (414.1 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

08/10/2024

[View](/mt/documents/product-information/orphacol-epar-product-information_mt.pdf)

Nederlands (NL) (368.55 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

08/10/2024

[View](/nl/documents/product-information/orphacol-epar-product-information_nl.pdf)

norsk (NO) (350.89 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

08/10/2024

[View](/no/documents/product-information/orphacol-epar-product-information_no.pdf)

polski (PL) (368.46 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

08/10/2024

[View](/pl/documents/product-information/orphacol-epar-product-information_pl.pdf)

português (PT) (405.22 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

08/10/2024

[View](/pt/documents/product-information/orphacol-epar-product-information_pt.pdf)

română (RO) (411.68 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

08/10/2024

[View](/ro/documents/product-information/orphacol-epar-product-information_ro.pdf)

slovenčina (SK) (391.14 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

08/10/2024

[View](/sk/documents/product-information/orphacol-epar-product-information_sk.pdf)

slovenščina (SL) (352.98 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

08/10/2024

[View](/sl/documents/product-information/orphacol-epar-product-information_sl.pdf)

Suomi (FI) (355.08 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

08/10/2024

[View](/fi/documents/product-information/orphacol-epar-product-information_fi.pdf)

svenska (SV) (346.61 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

08/10/2024

[View](/sv/documents/product-information/orphacol-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** PSUSA-10208-202409 10/04/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Orphacol : EPAR - All Authorised presentations

English (EN) (81.55 KB - PDF)

**First published:** 02/10/2013

**Last updated:** 06/10/2017

[View](/en/documents/all-authorised-presentations/orphacol-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-694)

български (BG) (87.45 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

06/10/2017

[View](/bg/documents/all-authorised-presentations/orphacol-epar-all-authorised-presentations_bg.pdf)

español (ES) (82.12 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

06/10/2017

[View](/es/documents/all-authorised-presentations/orphacol-epar-all-authorised-presentations_es.pdf)

čeština (CS) (84.2 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

06/10/2017

[View](/cs/documents/all-authorised-presentations/orphacol-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (84.16 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

06/10/2017

[View](/da/documents/all-authorised-presentations/orphacol-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (84.28 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

06/10/2017

[View](/de/documents/all-authorised-presentations/orphacol-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (80.82 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

06/10/2017

[View](/et/documents/all-authorised-presentations/orphacol-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (86.68 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

06/10/2017

[View](/el/documents/all-authorised-presentations/orphacol-epar-all-authorised-presentations_el.pdf)

français (FR) (83.56 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

06/10/2017

[View](/fr/documents/all-authorised-presentations/orphacol-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (286.06 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

06/10/2017

[View](/hr/documents/all-authorised-presentations/orphacol-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (83.8 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

06/10/2017

[View](/is/documents/all-authorised-presentations/orphacol-epar-all-authorised-presentations_is.pdf)

italiano (IT) (81.48 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

06/10/2017

[View](/it/documents/all-authorised-presentations/orphacol-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (84.17 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

06/10/2017

[View](/lv/documents/all-authorised-presentations/orphacol-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (84.83 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

06/10/2017

[View](/lt/documents/all-authorised-presentations/orphacol-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (86.94 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

06/10/2017

[View](/hu/documents/all-authorised-presentations/orphacol-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (85.2 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

06/10/2017

[View](/mt/documents/all-authorised-presentations/orphacol-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (80.34 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

06/10/2017

[View](/nl/documents/all-authorised-presentations/orphacol-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (84.65 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

06/10/2017

[View](/no/documents/all-authorised-presentations/orphacol-epar-all-authorised-presentations_no.pdf)

polski (PL) (84.3 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

06/10/2017

[View](/pl/documents/all-authorised-presentations/orphacol-epar-all-authorised-presentations_pl.pdf)

português (PT) (83.46 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

06/10/2017

[View](/pt/documents/all-authorised-presentations/orphacol-epar-all-authorised-presentations_pt.pdf)

română (RO) (82.69 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

06/10/2017

[View](/ro/documents/all-authorised-presentations/orphacol-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (85.09 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

06/10/2017

[View](/sk/documents/all-authorised-presentations/orphacol-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (81.91 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

06/10/2017

[View](/sl/documents/all-authorised-presentations/orphacol-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (81.39 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

06/10/2017

[View](/fi/documents/all-authorised-presentations/orphacol-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (82.14 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

06/10/2017

[View](/sv/documents/all-authorised-presentations/orphacol-epar-all-authorised-presentations_sv.pdf)

Orphacol : EPAR - Conditions imposed on member states for safe and effective use

English (EN) (41.66 KB - PDF)

**First published:** 02/10/2013

**Last updated:** 02/10/2013

[View](/en/documents/conditions-member-states/orphacol-epar-conditions-imposed-member-states-safe-and-effective-use_en.pdf)

[Other languages (24)](#file-language-dropdown-543)

български (BG) (82.69 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/bg/documents/conditions-member-states/orphacol-epar-conditions-imposed-member-states-safe-and-effective-use_bg.pdf)

español (ES) (41.62 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/es/documents/conditions-member-states/orphacol-epar-conditions-imposed-member-states-safe-and-effective-use_es.pdf)

čeština (CS) (81.69 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/cs/documents/conditions-member-states/orphacol-epar-conditions-imposed-member-states-safe-and-effective-use_cs.pdf)

dansk (DA) (39.22 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/da/documents/conditions-member-states/orphacol-epar-conditions-imposed-member-states-safe-and-effective-use_da.pdf)

Deutsch (DE) (40.49 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/de/documents/conditions-member-states/orphacol-epar-conditions-imposed-member-states-safe-and-effective-use_de.pdf)

eesti keel (ET) (41.23 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/et/documents/conditions-member-states/orphacol-epar-conditions-imposed-member-states-safe-and-effective-use_et.pdf)

ελληνικά (EL) (79.61 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/el/documents/conditions-member-states/orphacol-epar-conditions-imposed-member-states-safe-and-effective-use_el.pdf)

français (FR) (42.38 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/fr/documents/conditions-member-states/orphacol-epar-conditions-imposed-member-states-safe-and-effective-use_fr.pdf)

hrvatski (HR) (60.94 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/hr/documents/conditions-member-states/orphacol-epar-conditions-imposed-member-states-safe-and-effective-use_hr.pdf)

íslenska (IS) (27.3 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/is/documents/conditions-member-states/orphacol-epar-conditions-imposed-member-states-safe-and-effective-use_is.pdf)

italiano (IT) (41.57 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/it/documents/conditions-member-states/orphacol-epar-conditions-imposed-member-states-safe-and-effective-use_it.pdf)

latviešu valoda (LV) (73.51 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/lv/documents/conditions-member-states/orphacol-epar-conditions-imposed-member-states-safe-and-effective-use_lv.pdf)

lietuvių kalba (LT) (74.75 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/lt/documents/conditions-member-states/orphacol-epar-conditions-imposed-member-states-safe-and-effective-use_lt.pdf)

magyar (HU) (61.96 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/hu/documents/conditions-member-states/orphacol-epar-conditions-imposed-member-states-safe-and-effective-use_hu.pdf)

Malti (MT) (82.56 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/mt/documents/conditions-member-states/orphacol-epar-conditions-imposed-member-states-safe-and-effective-use_mt.pdf)

Nederlands (NL) (41.76 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/nl/documents/conditions-member-states/orphacol-epar-conditions-imposed-member-states-safe-and-effective-use_nl.pdf)

norsk (NO) (41.54 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/no/documents/conditions-member-states/orphacol-epar-conditions-imposed-member-states-safe-and-effective-use_no.pdf)

polski (PL) (72.82 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/pl/documents/conditions-member-states/orphacol-epar-conditions-imposed-member-states-safe-and-effective-use_pl.pdf)

português (PT) (42.63 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/pt/documents/conditions-member-states/orphacol-epar-conditions-imposed-member-states-safe-and-effective-use_pt.pdf)

română (RO) (72.3 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/ro/documents/conditions-member-states/orphacol-epar-conditions-imposed-member-states-safe-and-effective-use_ro.pdf)

slovenčina (SK) (73.01 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/sk/documents/conditions-member-states/orphacol-epar-conditions-imposed-member-states-safe-and-effective-use_sk.pdf)

slovenščina (SL) (69.08 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/sl/documents/conditions-member-states/orphacol-epar-conditions-imposed-member-states-safe-and-effective-use_sl.pdf)

Suomi (FI) (40.82 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/fi/documents/conditions-member-states/orphacol-epar-conditions-imposed-member-states-safe-and-effective-use_fi.pdf)

svenska (SV) (39.25 KB - PDF)

**First published:**

02/10/2013

**Last updated:**

02/10/2013

[View](/sv/documents/conditions-member-states/orphacol-epar-conditions-imposed-member-states-safe-and-effective-use_sv.pdf)

## Product details

Name of medicine Orphacol Active substance cholic acid International non-proprietary name (INN) or common name cholic acid Therapeutic area (MeSH)

- Digestive System Diseases
- Metabolism, Inborn Errors

Anatomical therapeutic chemical (ATC) code A05AA03

### Pharmacotherapeutic group

Bile acids and derivatives

### Therapeutic indication

Orphacol is indicated for the treatment of inborn errors in primary bile-acid synthesis due to 3?-hydroxy-? 5 -C 27 -steroid oxidoreductase deficiency or ? 4 -3-oxosteroid-5?-reductase deficiency in infants, children and adolescents aged one month to 18 years and adults.

## Authorisation details

EMA product number EMEA/H/C/001250

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Exceptional circumstances

This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see [Pre-authorisation guidance](/node/68554) .

Marketing authorisation holder

Theravia

16 rue Montrosier

Opinion adopted 16/12/2010 Marketing authorisation issued 12/09/2013 Revision 15

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Orphacol : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (256.16 KB - PDF)

**First published:** 10/12/2013

**Last updated:** 11/04/2025

[View](/en/documents/procedural-steps-after/orphacol-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Orphacol : EPAR - Public assessment report

Adopted

Reference Number: EMA/596651/2013

English (EN) (639.35 KB - PDF)

**First published:** 02/10/2013

**Last updated:** 02/10/2013

[View](/en/documents/assessment-report/orphacol-epar-public-assessment-report_en.pdf)

#### More information on Orphacol

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu-3-02-127) on 18 December 2002. Orphacol was withdrawn from the Community register of orphan medicinal products in September 2023 at the end of the 10-year period of market exclusivity.

#### More information on Orphacol

- [Orphacol® patient surveillance database (Orphabase) - post-authorisation study](https://catalogues.ema.europa.eu/study/49962)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 11/04/2025

## Share this page

[Back to top](#main-content)